Hi Guest Login
Home > Tests > Ataxia Telangiectasia del/dup byMLPA(MG) > Panchkula
₹11440 ₹11440
Report Time
4 weeksFREE
Home Sample Collection
Age Group
Parameters Included
Recomended for
Both
Fasting
No Fasting Required
Report Time
4 weeks
Exclusive Offer
₹11440
₹11440
FREE Home Sample Collection*
FREE Smart Report
Get a callback from our Health advisor.
Understanding the Test
Test Measures
City Price Info
The Ataxia Telangiectasia del/dup by MLPA (MG) Test is an advanced genetic test designed to identify large deletions and duplications in the ATM gene, which are associated with Ataxia Telangiectasia (A-T) and certain hereditary cancer syndromes. By analyzing copy number variations that may not be detected through routine gene sequencing, this test provides valuable insights for accurate diagnosis, carrier screening, risk assessment, and genetic counselling. It plays an important role in evaluating individuals with suspected ATM-related disorders and families with a history of inherited cancer risk.
The Ataxia Telangiectasia del/dup by MLPA (MG) test measures copy number variations (CNVs), including deletions and duplications, within the ATM(AtaxiaTelangiectasiaMutated) gene. Using Multiplex Ligation-dependent Probe Amplification (MLPA) with an MG-series probemix, the test evaluates all 66 exons of the ATM gene to identify missing or extra genetic material that may affect normal gene function. It assesses exon-level deletions and duplications, compares DNA copy number ratios to reference samples for quantitative analysis, and covers known breakpoint regions prone to genetic alterations. These measurements help detect genetic changes associated with Ataxia-Telangiectasia and hereditary cancer predisposition syndromes linked to ATM gene abnormalities.
The Ataxia Telangiectasia del/dup by MLPA (MG) test is a specialized molecular genetic test used to detect large deletions and duplications (copy number variations) in the ATM gene on chromosome 11q22-23. It uses MLPA technology with a validated MRC-Holland probemix kit (MG series) to identify exon-level copy number changes.
This test is vital for diagnosing Ataxia Telangiectasia (A-T) and identifying carriers who may not show classic symptoms but have a significant hereditary cancer risk.
A rare inherited disorder caused by mutations in the ATM gene. It leads to early-onset coordination problems, eye and skin telangiectasias, immune deficiency, and increased cancer risk. MLPA detects gene deletions or duplications.
Individuals with a single altered ATM gene are generally neurologically unaffected but have an elevated lifetime risk of breast cancer, pancreatic cancer, and other ATM-associated malignancies. MLPA accurately identifies these variants for family screening.
ATM mutations can impair DNA repair and immune cell development, leading to recurrent infections, reduced immunoglobulin levels, and lymphopenia. MLPA confirms the genetic basis of immunodeficiency.
Pathogenic ATM variants are associated with hereditary cancer syndromes, including breast and pancreatic cancers. Detecting these variants supports early surveillance, preventive care, and informed decisions for families.
|
Parameter |
Details |
|
Test Name |
Ataxia Telangiectasia del/dup by MLPA (MG) |
|
Also Known As |
ATM Gene Deletion/Duplication Analysis by MLPA; ATM MLPA (MG Kit) |
|
Sample Type |
Blood (EDTA) |
|
Gender |
Both |
|
Age Group |
All |
|
Fasting Required |
No |
|
Report Time |
10–15 Working Days |
|
Home Collection |
Available |
Schedule your home visit via website, app, or helpline at your convenience.
A certified phlebotomist collects a blood sample using a sterile EDTA Vacutainer quickly and hygienically.
The sample is transported under controlled conditions to NABL-accredited labs, where trained molecular geneticists perform DNA extraction and MLPA analysis.
A comprehensive report with interpretation is delivered within 10–15 working days via email, WhatsApp, and the MAX@Home app. Genetic counselling support is available.
No deletions or duplications detected across ATM exons. Further sequencing may be needed if suspicion remains.
Heterozygous variants indicate carrier status and cancer risk. Homozygous or compound variants support A-T diagnosis.
Reports are available within 4 weeks of sample receipt at the laboratory.
Delivered via
MAX@Home App
Our trained, background-verified phlebotomists follow strict aseptic protocols for blood collection, ensuring sample integrity for accurate molecular genetic analysis.
All MLPA analyses are performed in NABL-accredited molecular genetics laboratories using validated MRC-Holland MG-series probemix kits, ensuring results that meet the highest national quality standards.
Our molecular geneticists use industry-standard Coffalyser software for MLPA data analysis, with stringent internal quality controls and result verification processes before every report is issued.
From booking to report delivery, our entire process is designed for your comfort. No hospital queues, no parking hassles, just professional doorstep service across Panchkula and NCR.
MAX@Home is backed by the trusted MAX Healthcare network, with years of experience in diagnostic excellence and patient-centric care, making us the preferred choice for rare disease genetic testing in Panchkula.
Early detection of ATM gene alterations plays a crucial role in accurate diagnosis, timely intervention, cancer risk assessment, and long-term care planning for you and your family.
Read More
You've selected items to compare.
View All